Intellia Therapeutics (NTLA) just unveiled an announcement.
Intellia Therapeutics, Inc. has announced the appointment of Edward Dulac as the new Executive Vice President and Chief Financial Officer, effective July 22, 2024. Dulac, with over 20 years of experience in finance and business development, previously served at Fate Therapeutics and held multiple roles at Celgene. His remuneration includes a $510,000 base salary, up to 40% annual bonus, a one-time $100,000 sign-on bonus, and substantial initial equity awards. Outgoing CFO, Glenn Goddard, will depart on June 30, 2024, with no disagreements cited. Michael P. Dube will act as interim principal financial officer until Dulac assumes his role.
See more data about NTLA stock on TipRanks’ Stock Analysis page.
